Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT03602898 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT03602898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03602898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
June 1, 2021
Completion date
September 17, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia in remission, acute myeloid leukemia arising from previous myelodysplastic syndrome, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, hematopoietic and lymphoid system neoplasm, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasm, recurrent acute myeloid leukemia, recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, refractory acute myeloid leukemia, therapy-related acute myeloid leukemia